SynthesisFrontiers in endocrinology2022

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials.

Feifei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.